Skopos Labs, Inc. Collegium Pharmaceutical, Inc Transaction History
Skopos Labs, Inc.
- $330 Million
- Q4 2024
A detailed history of Skopos Labs, Inc. transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Skopos Labs, Inc. holds 82 shares of COLL stock, worth $2,734. This represents 0.0% of its overall portfolio holdings.
Number of Shares
82Holding current value
$2,734% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding COLL
# of Institutions
250Shares Held
36.7MCall Options Held
100KPut Options Held
21.1K-
Black Rock Inc. New York, NY5.79MShares$193 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$87.9 Million1.79% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.59MShares$86.4 Million0.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.35MShares$78.3 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.66MShares$55.2 Million0.1% of portfolio
About COLLEGIUM PHARMACEUTICAL, INC
- Ticker COLL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 34,126,200
- Market Cap $1.14B
- Description
- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...